Head-to-head evidence
Ertugliflozin vs janagliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Ertugliflozin · Steglatro
Marketed by Merck & Co. and partners
NCT01986881 · Phase 3 · completed
This trial was randomized, double-blind, and placebo-controlled with over 8,000 participants, giving it strong statistical power, and its primary endpoint was a hard clinical composite (cardiovascular death, non-fatal MI, or non-fatal stroke) rather than a lab surrogate. The trial was designed as a cardiovascular-safety non-inferiority study, and the pre-specified margin was met, with the ertugliflozin-placebo hazard ratio's upper confidence bound (1.114) falling below the 1.3 non-inferiority threshold, demonstrating that ertugliflozin does not increase cardiovascular risk versus placebo in this population.
Next expected readout: January 2028 · NCT07621380 (registry estimate)
janagliflozin
Developed by Sihuan Pharmaceutical Holdings
NCT03811548 · Phase 3 · status unknown
This randomized, double-blind, placebo-controlled trial enrolled 442 patients and measured change in HbA1c, a standard diabetes efficacy measure, at 24 weeks. Both the 25 mg and 50 mg doses of janagliflozin significantly outperformed placebo (p<0.001 for both), exceeding the trial's pre-specified superiority margin.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ertugliflozin's landscape · janagliflozin's landscape